Grant: Project Grant
Research Institute of the McGill University Health Centre
$715,275.00
Effectiveness and Safety of Long-term Antiresorptive Treatment for Osteoporosis in Canada: Improving Shared Decision Making
EF 2022-23
Résumé
Over the last 50 years, there have been major advances in the management of osteoporosis. Despite this, more than 80% of Canadians at high fracture risk do not receive guidelines- based treatments that have been shown to be cost-effective. This substantial care gap reveals important barriers to effective knowledge mobilization such as the lack of evidence on the long-term benefits and safety of anti-osteoporosis medications and the lack of tools to inform shared decision-making in clinical practice.
In collaboration with patient partners and healthcare professionals, we will develop a decision aid that integrates longer-term benefits/harms of first-line treatment with recently updated Canadian guidance on risk assessment, osteoporosis management and fracture prevention to reduce the care gap.
Programme
Project Grant
Emplacement
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
479315
Name
Morin Suzanne N
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Services Evaluation & Interventions Research 3
Projecttitle
Effectiveness and Safety of Long-term Antiresorptive Treatment for Osteoporosis in Canada: Improving Shared Decision Making
Programtype2
Operating Grants
Orgnameinp2
Research Institute of the McGill University Health Centre
Cihramount2
$715,275
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Administrative Data Analysis; Antiresorptive Drug Therapy; Bone Mineral Density; Cohort Study; Fractures; Osteoporosis; Safety; Shared Decision Making
Abstract
Over the last 50 years, there have been major advances in the management of osteoporosis. Despite this, more than 80% of Canadians at high fracture risk do not receive guidelines- based treatments that have been shown to be cost-effective. This substantial care gap reveals important barriers to effective knowledge mobilization such as the lack of evidence on the long-term benefits and safety of anti-osteoporosis medications and the lack of tools to inform shared decision-making in clinical practice.
In collaboration with patient partners and healthcare professionals, we will develop a decision aid that integrates longer-term benefits/harms of first-line treatment with recently updated Canadian guidance on risk assessment, osteoporosis management and fracture prevention to reduce the care gap.
Competitiondate
202303
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Morin, Suzanne N; Leslie, William D; Lix, Lisa M
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $715,275~ $0~
